PDF(Pubmed)
Abstract：
Colorectal cancer (CRC) is the second leading cause of cancer deaths in Spain. Metastatic disease is present in 15-30% of patients at diagnosis and up to 20-50% of those with initially localized disease eventually develop metastases. Recent scientific knowledge acknowledges that this is a clinically and biologically heterogeneous disease. As treatment options increase, prognosis for individuals with metastatic disease has steadily improved over recent decades. Disease management should be discussed among experienced, multidisciplinary teams to select the most appropriate systemic treatment (chemotherapy and targeted agents) and to integrate surgical or ablative procedures, when indicated. Clinical presentation, tumor sidedness, molecular profile, disease extension, comorbidities, and patient preferences are key factors when designing a customized treatment plan. These guidelines seek to provide succinct recommendations for managing metastatic CRC.
摘要：
结肠直肠癌（CRC）是西班牙癌症死亡的第二大原因。转移性疾病在诊断时存在于15-30%的患者中,并且高达20-50%的具有最初局部疾病的患者最终发展为转移。最近的科学知识承认这是一种临床和生物异质性疾病。随着治疗选择的增加，近几十年来，转移性疾病患者的预后稳步改善。疾病管理应该在有经验的人中讨论，多学科团队选择最合适的全身治疗（化疗和靶向药物），并整合手术或消融程序，当指示。临床表现,肿瘤侧面，分子分布,疾病扩展,合并症,和患者偏好是设计定制治疗计划时的关键因素。这些指南旨在为转移性CRC的管理提供简洁的建议。
